106 related articles for article (PubMed ID: 30755816)
1. Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment.
Mao MJ; Leonardi DE
Am J Cancer Res; 2019; 9(1):122-133. PubMed ID: 30755816
[TBL] [Abstract][Full Text] [Related]
2. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
3. D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
Cao C; Zhang L; Sorensen MD; Reifenberger G; Kristensen BW; McIntyre TM; Lin F
J Neuropathol Exp Neurol; 2023 Oct; 82(11):921-933. PubMed ID: 37740942
[TBL] [Abstract][Full Text] [Related]
4. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
[TBL] [Abstract][Full Text] [Related]
5. Monitoring response to a clinically relevant IDH inhibitor in glioma-Hyperpolarized
Hong D; Kim Y; Mushti C; Minami N; Wu J; Cherukuri MK; Swenson RE; Vigneron DB; Ronen SM
Neurooncol Adv; 2023; 5(1):vdad143. PubMed ID: 38024238
[TBL] [Abstract][Full Text] [Related]
6.
Ponomarova O; Starbard AN; Belfi A; Anderson AV; Sundaram MV; Walhout AJM
bioRxiv; 2024 Mar; ():. PubMed ID: 38559246
[TBL] [Abstract][Full Text] [Related]
7. Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation.
Taub M; Mahmoudzadeh NH; Tennessen JM; Sudarshan S
Front Endocrinol (Lausanne); 2022; 13():932286. PubMed ID: 36133305
[TBL] [Abstract][Full Text] [Related]
8. α-Ketoglutarate supplementation and NAD+ modulation enhance metabolic rewiring and radiosensitization in SLC25A1 inhibited cancer cells.
Xiang K; Kunin M; Larafa S; Busch M; Dünker N; Jendrossek V; Matschke J
Cell Death Discov; 2024 Jan; 10(1):27. PubMed ID: 38225236
[TBL] [Abstract][Full Text] [Related]
9. Electrochemical Nanoreactor Provides a Comprehensive View of Isocitrate Dehydrogenase Cancer-drug Kinetics.
Herold RA; Schofield CJ; Armstrong FA
Angew Chem Int Ed Engl; 2023 Oct; 62(42):e202309149. PubMed ID: 37607127
[TBL] [Abstract][Full Text] [Related]
10. Electrochemical Nanoreactor Provides a Comprehensive View of Isocitrate Dehydrogenase Cancer-drug Kinetics.
Herold RA; Schofield CJ; Armstrong FA
Angew Chem Weinheim Bergstr Ger; 2023 Oct; 135(42):e202309149. PubMed ID: 38529044
[TBL] [Abstract][Full Text] [Related]
11. Sphingolipid Pathway as a Source of Vulnerability in IDH1
Dowdy T; Zhang L; Celiku O; Movva S; Lita A; Ruiz-Rodado V; Gilbert MR; Larion M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050528
[TBL] [Abstract][Full Text] [Related]
12. Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity.
Feng S; Wang D; Jin Y; Huang S; Liang T; Sun W; Du X; Zhuo L; Shan C; Zhang W; Jing T; Zhao S; Hong R; You L; Liu G; Chen L; Ye D; Li X; Yang Y
Cell Rep; 2024 Jun; 43(6):114300. PubMed ID: 38829739
[TBL] [Abstract][Full Text] [Related]
13. L-2-hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models.
Kundu A; Brinkley GJ; Nam H; Karki S; Kirkman R; Pandit M; Shim E; Widden H; Liu J; Heidarian Y; Mahmoudzadeh NH; Fitt AJ; Absher D; Ding HF; Crossman DK; Placzek WJ; Locasale JW; Rakheja D; McConathy JE; Ramachandran R; Bae S; Tennessen JM; Sudarshan S
J Clin Invest; 2024 May; ():. PubMed ID: 38743486
[TBL] [Abstract][Full Text] [Related]
14. Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models.
Rajani K; Olson I; Jacobs JJ; Riviere-Cazaux C; Burns K; Carlstrom L; Schroeder M; Oh J; Howe CL; Rahman M; Sarkaria JN; Elmquist WF; Burns TC
J Neurosci Methods; 2021 Nov; 363():109321. PubMed ID: 34390758
[TBL] [Abstract][Full Text] [Related]
15. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
[TBL] [Abstract][Full Text] [Related]
16. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells.
Gerecke C; Schumacher F; Berndzen A; Homann T; Kleuser B
Epigenetics; 2020 Mar; 15(3):307-322. PubMed ID: 31505989
[TBL] [Abstract][Full Text] [Related]
17. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
19. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
Gargini R; Segura-Collar B; Herránz B; García-Escudero V; Romero-Bravo A; Núñez FJ; García-Pérez D; Gutiérrez-Guamán J; Ayuso-Sacido A; Seoane J; Pérez-Núñez A; Sepúlveda-Sánchez JM; Hernández-Laín A; Castro MG; García-Escudero R; Ávila J; Sánchez-Gómez P
Sci Transl Med; 2020 Jan; 12(527):. PubMed ID: 31969485
[TBL] [Abstract][Full Text] [Related]
20. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
